

Protinádorová chemoterapeutika

Tremorogenních je také několik protinádorových chemoterapeutik – thalidomid s mírným reverzibilním třesem (50), cytarabin s třesem v terénu cerebelárního syndromu v důsledku toxicity přípravku pro Purkyňovy buňky (51), cisplatina a tamoxifen (1).

LITERATURA

1. Morgan JC, Sethi KD. Drug-induced tremors. *Lancet Neurol.* 2005;4(12):866-876.
2. Factor SA. Lithium-induced movement disorders. In: *Drug-induced movement disorders.* CRC Press; 2004. s. 226-249.
3. Sethi KD, Patel B, Meador KJ. Metoclopramide-induced parkinsonism. *South Med J.* 1989;82(12):1581-1582.
4. Sethi KD, Zamrini EY. Asymmetry in clinical features of drug-induced parkinsonism. *J Neuropsychiatry Clin Neurosci.* 1990;2(1):64-66.
5. Baizabal-Carvallo JF, Morgan JC. Drug-induced tremor, clinical features, diagnostic approach and management. *J Neurol Sci.* 2022;435:120192.
6. Langone A, Steinberg SM, Gedaly R, Chan LK, Shah T, Sethi KD, et al. Switching Study of Kidney Transplant Patients with Tremor to LCP-TacR (STRATO): an open-label, multicenter, prospective phase 3b study. *Clin Transplant.* 2015;29(9):796-805.
7. Morgan JC, Kurek JA, Davis JL, Sethi KD. Insights into pathophysiology from medication-induced tremor. *Tremor Hyperkinetic Mov.* 2017;7.
8. Bongard V, Marc D, Philippe V, Jean-Louis M, Maryse LM. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. *Am J Ther.* 2006;13(4):315-319.
9. Hilleman D, Miller MA, Parker R, Doering P, Pieper JA. Optimal management of amiodarone therapy: efficacy and side effects. *Pharmacother J Hum Pharmacol Drug Ther.* 1998;18(6P2):1385-1455.
10. Harris L, McKenna WJ, Rowland E, Krikler DM. Side effects and possible contraindications of amiodarone use. *Am Heart J.* 1983;106(4):916-923.
11. Brien JF, Jimmo S, Brennan FJ, Ford SE, Armstrong PW. Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. *Can J Physiol Pharmacol.* 1987;65(3):360-364.
12. Werner EG, Olanow CW. Parkinsonism and amiodarone therapy. *Ann Neurol Off J Am Neurol Assoc Child Neurol Soc.* 1989;25(6):630-632.
13. Diaz-Martinez A, Benassinni O, Ontiveros A, Gonzalez S, Salin R, Basquedano G, et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. *Clin Ther.* 1998;20(3):467-476.
14. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. *Lancet Psychiatry.* 2019;6(6):538-546.
15. Gareil N, Greenway KT, Tabbane K, Joobar R. Serotonin syndrome: SSRIs are not the only culprit. *J Psychiatry Neurosci.* 2021;46(3):E369-70.
16. Watanabe S, Yokoyama S, Kubo S, Iwai H, Kuyama C. A double-blind controlled study of clinical efficacy of maprotiline and amitriptyline in depression. *Psychiatry Clin Neurosci.* 1978;32(1):1-31.
17. Baek JH, Kinrys G, Nierenberg AA. Lithium tremor revisited: pathophysiology and treatment. *Acta Psychiatr Scand.*

Závěr

Polékové třesy nejsou vzácností v klinické praxi i vzhledem k relativně četnému použití přípravků, které mohou třes vyvolávat. Značná část polékových třesů má charakter akcentovaného fyziologického třesu, ale lékaři by neměli zapomínat na možnost exacerbace nebo akcentace preexistujícího esenciálního třesu nebo rozvíjející se Parkinsonovy nemoci,

kdy nasazením suspektního přípravku došlo pouze k demaskování do té doby skrytého onemocnění. Diferenciální diagnostika tudíž musí pomýšlet i na tyto případy. Hypotézy o velice různorodých potenciálních mechanismech rozvoje tohoto nežádoucího účinku však v neposlední řadě poskytují zajímavý přehled mechanismů a struktur, které mohou fungovat jako generátory třesu.

- 2014;129(1):17-23.
18. Zadikoff C, Munhoz RP, Asante AN, Politzer N, Wennberg R, Carlen P, et al. Movement disorders in patients taking anticonvulsants. *J Neurol Neurosurg Psychiatry.* 2007;78(2):147-151.
19. Zhang CQ, He BM, Hu ML, Sun HB. Risk of valproic acid-related tremor: a systematic review and meta-analysis. *Front Neurol.* 2020;11:576579.
20. Paparella G, Angelini L, De Biase A, Cannavacciuolo A, Collella D, Di Bonaventura C, et al. Clinical and kinematic features of valproate-induced tremor and differences with essential tremor. *The Cerebellum.* 2021;20(3):374-383.
21. Kovács A, Farkas Z, Kelemen A, Juhos V, Szűcs A, Kamondi A. Lamotrigine induces tremor among epilepsy patients probably via cerebellar pathways. *Tohoku J Exp Med.* 2019;248(4):273-284.
22. Alonso-Navarro H, Jiménez-Jiménez FJ. Reversible tremor, myoclonus, and fasciculations associated with topiramate use for migraine. *Clin Neuropharmacol.* 2006;29(3):157-159.
23. Rissardo JP, Caprara ALF. Pregabalin-associated movement disorders: A literature review. *Brain Circ.* 2020;6(2):96.
24. Shanker V. Essential tremor: diagnosis and management. *bmj.* 2019;366.
25. Mazer B, Figueroa-Rosario W, Bender B. The effect of albuterol aerosol on fine-motor performance in children with chronic asthma. *J Allergy Clin Immunol.* 1990;86(2):243-248.
26. Mann RD, Kubota K, Pearce G, Wilton L. Salmeterol: a study by prescription event monitoring in a UK cohort of 15,407 patients. *J Clin Epidemiol.* 1996;49(2):247-250.
27. Baker MR, Baker SN. Beta-adrenergic modulation of tremor and corticomuscular coherence in humans. *PLoS One.* 2012;7(11):e49088.
28. Sethi KD. Movement disorders induced by dopamine blocking agents. In: *Seminars in neurology.* Copyright/copyright 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New ...; 2001. s. 059-68.
29. Stacy M, Jankovic J. Tardive tremor. *Mov Disord Off J Mov Disord Soc.* 1992;7(1):53-57.
30. Kertesz DP, Swartz MV, Tadger S, Ploski I, Barak Y. Tetraabenazine for tardive tremor in elderly adults: a prospective follow-up study. *Clin Neuropharmacol.* 2015;38(1):23-25.
31. Calne DB, Webster RA. Tremor induced by tetraabenazine. *Br J Pharmacol.* 1969;37(2):468.
32. Acharya SR, Kumar TN, Vassadhara C. Metoclopramide-a cholinomimetic tremorogen? In: *Metoclopramide-a cholinomimetic tremorogen?* 1982.
33. Graber DJ, Meier KH. Acute misoprostol toxicity. *Ann Emerg Med.* 1991;20(5):549-551.
34. Bateman DN, Bevan P, Longley BP, Mastaglia F, Wandless I. Cimetidine induced postural and action tremor. *J Neurol Neurosurg Psychiatry.* 1981;44(1):94.
35. Mandel SH, Magnusson AR, Burton BT, Swanson JR, LaFran-

- chi SH. Massive levothyroxine ingestion: conservative management. *Clin Pediatr (Phila).* 1989;28(8):374-376.
36. Abila B, Lazarus JH, Kingswood JC, Marshall RW, Wilson JF, Richens A. Tremor: an alternative approach for investigating adrenergic mechanisms in thyrotoxicosis? *Clin Sci Lond Engl.* 1979. 1985;69(4):459-463.
37. Falkson G, Falkson HC. A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer. *Cancer Chemother Pharmacol.* 1983;11(1):16-18.
38. Simons FER, Gu X, Silver NA, Simons KJ. EpiPen Jr versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxis. *J Allergy Clin Immunol.* 2002;109(1):171-175.
39. Gijtenbeek JM, Van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. *J Neurol.* 1999;246(5):339-346.
40. Wijidicks EF, Wiesner RH, Dahlke LJ, Krom RA. FK506-induced neurotoxicity in liver transplantation. *Ann Neurol Off J Am Neurol Assoc Child Neurol Soc.* 1994;35(4):498-501.
41. Sarasombath P, Sumida KN, Kaku DA. Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia. *Hawaii Med J.* 2002;61(3).
42. Vogrig A, Muñoz-Castrillo S, Joubert B, Picard G, Rogemond V, Marchal C, et al. Central nervous system complications associated with immune checkpoint inhibitors. *J Neurol Neurosurg Psychiatry.* 2020;91(7):772-778.
43. Xing F, Marsili L, Truong DD. Parkinsonism in viral, paraneoplastic, and autoimmune diseases. *J Neurol Sci.* 2022;433:120014.
44. Vogrig A, Fouret M, Joubert B, Picard G, Rogemond V, Pinto AL, et al. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. *Neurol Neuroimmunol Neuroinflammation.* 2019;6(6).
45. Borucki MJ, Matzke DS, Pollard RB. Tremor induced by trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome (AIDS). *Ann Intern Med.* 1988;109(1):77-78.
46. Burdge DR, Chow AW, Sacks SL. Neurotoxic effects during vidarabine therapy for herpes zoster. *Can Med Assoc J.* 1985;132(4):392.
47. Rashedi S, Brieu L, Mooney M, Giancarlo T, Khatib R, Wilson FM. Distinguishing acyclovir neurotoxicity from encephalomyelitis. *J Intern Med.* 1993;234(5):507-511.
48. Ellis WG, Sobel RA, Nielsen SL. Leukoencephalopathy in patients treated with amphotericin B methyl ester. *J Infect Dis.* 1982;146(2):125-137.
49. Quabeck K, Müller KD, Beelen DW, Dermoumi H, Köbel M, Kraft J, et al. Prophylaxis and treatment of fungal infections with fluconazole in bone marrow transplant patients. *Mycoses.* 1990;33(15):19-26.
50. Chiruka S, Chapman CS. Severe tremors associated with use of thalidomide. *Am J Hematol.* 2005;78(1):81-82.
51. Dworkin LA, Goldman RD, Zivin LS, Fuchs PC. Cerebellar toxicity following high-dose cytosine arabinoside. *J Clin Oncol.* 1985;3(5):613-616.